691-60-1Relevant articles and documents
METHODS OF TREATMENT WITH MYOSIN MODULATOR
-
Paragraph 565, (2021/05/15)
Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable salt thereof to a subject in need thereof and diagnostic methods useful in connection with those treatments. Due to observations unfolding in clinical trials with mavacamten and with mavacamten and other myosin inhibitors in the pre-clinical setting, new insights into how myosin inhibitors can be used beneficially to impact the disease state of HCM and other diseases are provided herein.
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00570, (2020/06/10)
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
Synthesis and Structure of 1-Substituted Semithioglycolurils
Baranov, Vladimir V.,Galochkin, Anton A.,Kravchenko, Angelina N.,Makhova, Nina N.,Nelyubina, Yulia V.
, p. 2563 - 2571 (2020/09/07)
Two methods for the synthesis of previously unavailable 1-substituted semithioglycolurils were developed. These methods consist of the cyclocondensation of 1-substituted ureas with 4,5-dihydroxy- or 4,5-dimethoxyimidazolidine-2-thione or glyoxal, followed by the reaction of the resulting 1-substituted 4,5-dihydroxyimidazolidine-2-ones with HSCN in a two-step one-pot procedure. Two of the desired semithioglycolurils were obtained as conglomerates.
